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Abstract
Background: Chemerin has been associated with psoriasis and inflammation, but there are no 
studies demonstrating an association between chemerin and subclinical cardiac involvement in psori-
atic patients. Therefore, the present study aimed to evaluate whether psoriatic patients with increased 
epicardial fat tissue, impaired flow-mediated dilatation, and diastolic dysfunction have higher serum 
chemerin levels than a healthy control group.
Methods: The study included 60 psoriatic patients and 32 healthy controls. Echocardiographic param-
eters, epicardial fat tissue, flow-mediated dilatation, and chemerin levels were recorded for both groups.
Results: The serum levels of chemerin in the psoriatic patients were significantly higher than in the 
control group. The diastolic function parameters, including isovolumic contraction and relaxation time, 
E’/A’ (early diastolic mitral annular velocity/late diastolic mitral annular velocity), and E/E’ (early 
diastolic peak velocity of mitral inflow/early diastolic mitral annular velocity) values, differed signifi-
cantly between the groups. Epicardial fat tissue was significantly higher and flow-mediated dilatation 
was significantly lower in psoriatic patients than in the controls. Chemerin was significantly positively 
correlated with age, body mass index, systolic and diastolic blood pressures, waist circumference, E/E’, 
and epicardial fat tissue. Serum chemerin was significantly negatively correlated with E’, E’/A’, and 
flow-mediated dilatation. A multiple linear regression analysis showed that chemerin was independently 
correlated with E/E’.
Conclusions: Psoriatic patients exhibit early subclinical atherosclerosis and diastolic dysfunction. 
Chemerin can be used as a marker to screen for patients with subclinical cardiac involvement. (Cardiol J  
2017; 24, 3: 276–283)
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Introduction
Chemerin, a novel chemokine that modulates 
activation and chemotaxis of dendritic cells, mac-
rophages, and neutrophils, is highly expressed in 
the liver and white adipose tissue [1]. In addition 
to its immunomodulatory effects, associations have 
been reported between chemerin and components 
of metabolic syndrome, including body mass in-
dex (BMI), plasma triglyceride (TG) levels, and 
hypertension [1, 2]. Recently, strong chemerin 
expression and increased plasmacytoid dendritic 
cells have been associated with psoriatic skin [3]. 
Psoriasis is a chronic inflammatory disease of the 
skin, affecting 2–3% of the world’s population [4]. 
It is known that psoriasis is associated with ear-
lier development of atherosclerosis and a higher 
prevalence of subclinical left ventricular (LV) dys-
function, even in those without traditional cardio-
vascular (CV) risk factors [5]. The main mechanism 
behind these conditions is the chronic inflamma-
tory process of psoriasis [6, 7]. In light of these 
findings, chemerin, which plays a role in psoriasis 
pathogenesis and has immunomodulatory effects, 
may be useful as an early marker of subclinical CV 
disease (CVD) in patients with psoriasis.
In chronic inflammatory diseases, including pso-
riasis and systemic lupus erythematosus, subclinical 
myocardial disease is identified with tissue Doppler 
imaging (TDI), a modified Doppler technique that 
enables direct measurement of myocardial contractile 
and relaxation velocities, with high reproducibility 
and ease of performance [8–10]. Measuring flow-
mediated dilatation (FMD) is a noninvasive method of 
detecting endothelial dysfunction, which is regarded 
as an early stage of atherosclerosis [11]. Epicardial 
fat tissue (EFT) is considered a metabolically ac-
tive endocrine organ that strongly influences both 
the formation and advancement of coronary artery 
disease [12–14].
Recent trials involving psoriatic patients have 
demonstrated that increased EFT and impaired 
FMD are related to increased risk of atheroscle-
rosis [15, 16]. However, there are no data on the 
association between serum chemerin levels and 
atherosclerosis risk and subclinical cardiac involve-
ment in psoriatic patients. 
The present study hypothesized that the 
serum chemerin level may be a potential novel 
early marker of atherosclerosis and subclinical 
myocardial dysfunction in patients with psoriasis. 
Therefore, the study aimed to evaluate whether 
psoriatic patients with increased EFT, impaired 
FMD, and diastolic dysfunction on TDI also have 
higher serum chemerin levels than a healthy con-
trol group.
Methods
Study population
The study enrolled consecutive patients with 
psoriasis who attended the outpatient clinic of the 
Dermatology Unit, Istanbul Medeniyet University, 
Faculty of Medicine, Goztepe Training and Re-
search Hospital, Istanbul, Turkey, between Janu-
ary 2014 and January 2015. These patients were 
compared with healthy volunteers. The exclusion 
criteria were age > 60 years, smoking, the pres-
ence of structural heart disease, systemic diseases 
indicating cardiac involvement (e.g., hypertension, 
hypo- or hyperthyroidism, diabetes mellitus, col-
lagenosis, or renal failure), CVD (e.g., prior myo-
cardial infarctions, peripheral artery disease, or 
stroke), dyslipidemia, other dermatologic diseases 
affecting the immune system, psoriatic arthritis, 
and use of biologic agents [17]. Also excluded were 
patients with left ventricular mass index (LVMI) 
of ≥ 125 g/m2 for men or ≥ 110 g/m2 for women, 
or a BMI of more than 35 kg/m2. Written informed 
consent was obtained from all patients before 
enrollment. The study protocol was approved by 
the institutional ethics committee, and the study 
was conducted according to the principles of the 
Declaration of Helsinki. 
Biochemical and clinical assessment
Measurements included total cholesterol, 
low-density lipoprotein cholesterol (LDL-C), high- 
-density lipoprotein cholesterol (HDL-C), TG, glu-
cose, and high-sensitivity C-reactive protein (hs-
-CRP) levels. BMI, waist circumference, systolic 
blood pressure (SBP), and diastolic blood pressure 
(DBP) were recorded according to standardized 
procedures. The extent of skin involvement was 
assessed using the Psoriasis Area and Severity 
Index (PASI) [18].
Chemerin measurement
To analyze the concentration of chemerin 
levels, commercial ELISA kits (Biovendor; Czech 
Republic) were used according to the manufac-
turer’s instructions. The intra-assay coefficient 
of variations (CoVs) of the chemerin assay were 
5.1% at 177.5 ng/mL and 7% at 263.6 ng/mL. The 
inter-assay CoVs of the chemerin assay were 8.3% 
at 140.6 ng/mL and 6.9% at 222.7 ng/mL. The as-
say sensitivity was 0.1 ng/mL and the upper limit 
of the standard was 8 ng/mL. Measurements were 
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taken using an ELISA plate reader (Multiscan Go; 
Thermo Fisher Scientific, Inc.; Waltham, MA, USA) 
and a plate washer (Thermo Fisher Scientific, Inc.). 
Each well absorbance was determined at 450 nm 
by plotting the mean absorbance (Y) of standards 
against the known concentration (X) of standards 
on alogarithmic scale. The results were reported 
as the concentration of chemerin (ng/mL) in the 
samples.
Echocardiographic evaluation
Echocardiographic evaluation of the study 
population was conducted with transthoracic echo-
cardiography using a GE Medical Systems VIVID 
3 SyncMaster 591S machine. M-mode, 2-dimen-
sional, and finally both standard and pulsed tis-
sue Doppler echocardiographic evaluations were 
performed with participants in the lateral decubi-
tus position. Recommendations of the American 
Society of Echocardiography were followed while 
performing the echocardiographic measurements. 
Echocardiography determined the following param-
eters: diastolic interventricular septal (IVS) and 
posterior wall (PW) thickness, left atrium (LA) 
diameter, LV end-systolic diameter (LVSD) and LV 
end-diastolic diameter (LVDD), ejection fraction 
(EF), late diastolic peak velocity of mitral inflow 
(A), early diastolic peak velocity of mitral inflow 
(E), E/A ratio, deceleration time (DT), isovolu-
mic contraction time (IVCT) and relaxation time 
(IVRT), ejection time (ET), late diastolic mitral 
annular velocity (A’), early diastolic mitral annular 
velocity (E’), E’/A’ ratio, E/E’ ratio, mitral annular 
systolic motion velocity (Sm), and mitral annular 
ejection time (ET’). The EFT was defined as the 
hypoechoic space on the right ventricular free wall 
on the parasternal long-axis view [19].
FMD measurement
Brachial artery measurements were taken by 
a qualified cardiologist who was blinded to previously 
obtained data. Ultrasonographic scanning was per-
formed using high-resolution B-mode equipment 
(Aplio XU; Toshiba; Glen Mills, PA, USA) with 
a 7.5-MHz linear transducer. The patients were 
examined in the morning, after fasting for 8 h with 
no alcohol or caffeine, and after 15 min of rest. The 
right arm was relaxed and placed in an extended 
position for analysis of the brachial artery 3–5 cm 
above the antecubital fossa. Arm position was not 
changed throughout the study, and the point on 
the arm at which an acceptable image had been 
obtained was marked for repeated use. A pneumatic 
tourniquet was placed approximately 3–5 cm above 
antecubital fossa, and 200 mm Hg of pressure was 
applied for 5 min. A second ultrasonographic scan 
was taken after sudden deflation of the cuff. The 
average of measurements taken at 30, 60, and 
90 s was calculated and used. The diameter change 
caused by FMD was expressed as the percentage 
change relative to that on initial resting scan [20].
Statistical analyses
All calculations were performed using the 
statistical software package SPSS 9 for Windows 
(SPSS; Chicago, IL, USA). The Kolmogorov- 
-Smirnov test was used to determine distribution of 
values, whether normal or not. Descriptive analyses 
were performed using mean and standard deviation 
for normally distributed variables, and medians and 
interquartile ranges for non-normally distributed 
variables. Either the Student’s t-test or the Mann-
Whitney U-test were used to compare parameters 
between groups, as appropriate. Pearson’s cor-
relation or Spearman’s rho correlation analyses 
were used to test possible associations between 
chemerin and the study variables, as appropriate. 
Multivariate linear regression models explored 
whether the association between chemerin and 
E/E’ was independent of age, SBP, DBP, waist cir-
cumference, glucose, and LDL-C levels. P < 0.05 
was considered as statistically meaningful.
Results
This study used data from 60 psoriatic patients 
(mean age 44 ± 14 years; 23 women, 37 men) 
and 32 control subjects (mean age 42 ± 8 years; 
16 women, 16 men). Neither age nor sex varied 
significantly between the two groups (p > 0.05). 
In addition, there were no statistically significant 
differences in BMI, waist circumference, SBP, or 
DBP between the two groups (Table 1). 
The serum levels of chemerin in the psoriatic 
patients were significantly higher than in the con-
trol group (332 ± 73 ng/mL vs. 301 ± 60 ng/mL; 
p = 0.04). The HDL-C values of the psoriatic patients 
were observed to be significantly lower than those 
of the controls (43 ± 12 mg/dL vs. 53 ± 15 mg/dL; 
p = 0.003). All other biochemical parameters of 
the psoriatic patients were similar to those of the 
control group (Table 1).
All patients had normal IVS thickness, PW 
thickness, and LVDD, LVSD, and EF measure-
ments, and there were no significant differences 
between the groups in IVS thickness, LVDD, LVSD, 
LA diameter, and EF. However, the PW thickness 
of the psoriatic patients was significantly greater 
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than that of the control group (9 ± 1.2 mm vs. 
8 ± 0.9 mm; p = 0.01).
In addition, the diastolic function parameters, 
including IVRT, E’/A’, and E/E’ values, differed 
significantly between the groups and were found 
to be impaired in psoriatic patients (Table 2). Fur-
thermore, EFT values of psoriatic patients were 
significantly higher than those of controls (0.33 ± 
± 0.13 cm vs. 0.25 ± 0.12 cm; p = 0.04). However, 
the percentage of FMD was significantly lower in 
psoriatic patients than in the controls (6.9 ± 2.7% 
vs. 11.8 ± 3.3%; p < 0.001).
A correlation analysis was conducted for the 
correlations between serum chemerin level and 
age, BMI, waist circumference, PASI score, SBP, 
DBP, total cholesterol, TG, LDL-C and HDL-C, 
glucose, hs-CRP, EFT, FMD, and the echocar-
diographic parameters. Chemerin was signifi-
cantly positively correlated with age, BMI, SBP, 
DBP, waist circumference, E/E’, and EFT. Serum 
chemerin was significantly negatively correlated 
with E’, E’/A’, and FMD (Table 3). No significant 
correlation was found between serum chemerin 
and other study variables.
A multiple linear regression analysis with E/E’ 
as the dependent covariate, and with other study 
variablesas independent covariates, including age, 
SBP, DBP, waist circumference, glucose, and LDL-C 
levels, showed that chemerin was independently 
correlated with E/E’ (Table 4).
Discussion
The present study demonstrated that serum 
chemerin levels, which are associated with the 
production of pro-inflammatory mediators, are 
significantly higher in psoriatic patients than in the 
healthy population. The results also showed that 
serum chemerin levels directly correlate with the 
predictors of subclinical atherosclerosis: increased 
EFT and impaired FMD and LV diastolic function 
parameters. In addition, serum chemerin levels 
are strongly associated with subclinical cardiac 
dysfunctionin psoriatic patients.
Psoriasis is a chronic inflammatory skin dis-
ease characterized by well-marked, erythematous, 
scaling plaques on the extremities and trunk [4]. 
Psoriasis not only negatively affects the patient’s 
quality of life, but its chronic inflammation also 
increases the risk of CV morbidity and mortality 
[21]. However, it is not only inflammation that 
could justify this association; recent evidence also 
suggests a role for autonomic CV system dysregu-
lation [22]. Therefore, early detection of subclinical 
atherosclerosis in patients with psoriasis would aid 
in reducing CV morbidity and mortality.
Chemerin has been described as a pro-inflam-
matory adipokine that is released by the white 
adipose tissue itself, and its serum levels have been 
found to be strongly associated with components of 
metabolic syndrome, including elevated BMI, TG, 
Table 1. Demographic characteristics and laboratory variables.
Psoriasis subjects
(n = 60)
Control subjects
(n = 32)
p
Age [years] 44 ± 14 42 ± 8 0.67
Gender: female/male 23/37 16/16 0.28
Psoriasis Area and Severity Index 9.89 ± 6.93
BMI [kg/m2] 27.2 ± 4.5 27.8 ± 4.4 0.56
Systolic BP [mm Hg] 120 (120–135) 127.5 (120–139.7) 0.29
Diastolic BP [mm Hg] 80 (70–85) 79 (70.2–80) 0.52
Glucose [mg/dL] 95 (89.5–107.5) 92 (89.2–96.7) 0.14
Total cholesterol [mg/dL] 194 ± 42 211 ± 50 0.1
LDL-C [mg/dL] 122 ± 35 128 ± 40 0.5
HDL-C [mg/dL] 43 ± 12 53 ± 15 0.003
Triglyceride [mg/dL] 123 (81–171) 99.5 (71.2–179.7) 0.27
hs-CRP [mg/dL] 0.99 ± 1.47 0.33 ± 0.27 0.008
Waist circumference [cm] 97 ± 12 98 ± 13 0.79
Chemerin [ng/mL] 332 ± 73 301 ± 60 0.04
Data are mean ± standard deviation (SD) or median interquartile range (IQR). F — female; M — man; BMI — body mass index; BP — blood pres-
sure; hs-CRP — highly sensitive C-reactive protein; HDL-C — high-density lipoprotein cholesterol; LDL-C — low-density lipoprotein cholesterol
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and blood pressure, and with obesity and diabetes 
mellitus [23, 24]. Despite the fact that atheroscle-
rosis risk factors were excluded from this study, 
to prevent them from being potential confounders, 
serum chemerin levels were found to be higher in 
psoriatic patients. In addition, this study results 
demonstrated a strong association between serum 
chemerin levels and age, BMI, SBP, DBP, and waist 
circumference.
Biyik et al. [25] identified the presence of 
LV diastolic dysfunction with mitral valve inflow 
measurements in psoriatic patients. However, in 
their study, blood pressure levels were significantly 
higher in psoriatic patients than in controls. One 
of the most common causes of diastolic dysfunc-
tion is hypertension. The present study found no 
significant differences in SBP and DBP between 
the two groups, and no LV diastolic dysfunction 
based on measurements of mitral valve inflow in 
the psoriatic patients. While the E wave velocity 
is dependent on preload and LA pressure, the 
E’ wave velocity is a reliable index of LV relaxation 
[26, 27]. Furthermore, the E/E’ ratio shows a better 
correlation with pulmonary capillary wedge pres-
Table 2. Echocardiographic parameters.
Control subjects (n = 32) Psoriasis subjects (n = 60) P
LA [mm] 35 ± 4 34 ± 4 0.38
IVS [mm] 9 (8–10) 9 (9–10) 0.05
PW [mm] 8 (7–8.5) 9 (7–8.5) 0.01
LVEDD [mm] 49 ± 4 48 ± 4 0.25
LVESD [mm] 31 ± 4 30 ± 3 0.07
EF [%] 65 ± 4 66 ± 4 0.18
E [m/s] 0.69 ± 0.11 0.71 ± 0.14 0.74
A [m/s] 0.54 ± 0.09 0.58 ± 0.14 0.14
DT [ms] 208 (192.5–256) 209 (175–257.5) 0.6
E/A 1.3 ± 0.3 1.2 ± 0.4 0.6
IVRT [ms] 87 ± 14 79 ± 14 0.02
IVCT [ms] 70 ± 13 71 ± 13 0.7
ET [ms] 264 ± 28 276 ± 22 0.07
E’ [cm/s] 15 ± 3 14 ± 4 0.2
A’ [cm/s] 12 ± 3 12 ± 4 0.6
E’/A’ 1.3 ± 0.5 1 ± 0.4 0.005
SM [cm/s] 12 ± 2.7 11 ± 2 0.12
ET’ [cm/s] 288 ± 24 294 ± 27 0.3
E/E’ 4.62 (3.9–5.6) 5.33 (4.56–5.91) 0.037
FMD [%] 11.64 ± 3.4 6.96 ± 2.5 < 0.001
EFT [cm] 0.28 (0.20–0.32) 0.31 (0.24–0.35) 0.04
Data are mean ± standard deviation (SD) or median interquartile range (IQR). LA — left atrium diameter; IVS — interventricular septal thick-
ness; PW — posterior wall thickness; LVEDD — left ventricular end-diastolic diameter; LVESD — left ventricular end-systolic diameter; EF — 
ejection fraction; E — early diastolic peak flow velocity; A — late diastolic peak flow velocity; DT — E-wave deceleration time; IVRT — isovo-
lumic relaxation time; IVCT — isovolumic contraction time; ET — ejection time; E’ — early diastolic mitral annular velocity; A’ — late diastolic 
mitral annular velocity; SM — mitral annular systolic motion velocity; ET’ — mitral annular ejection time; FMD — flow me diated dilatation; 
EFT — epicardial fat thickness
Table 3. Correlation analysis between chemerin 
and variables.
Variables r p 
Age 0.249 0.019
Body mass index 0.232 0.047
Systolic BP 0.264 0.023
Diastolic BP 0.378 0.001
Waist circumference 0.308 0.009
E’ –0.286 0.013
E’/A’ –0.272 0.026
E/E’ 0.257 0.027
EFT 0.303 0.017
FMD –0.296 0.025
BP — blood pressure; E — early diastolic peak flow velocity; E’ — 
early diastolic mitral annular velocity; A’ — late diastolic mitral an-
nular velocity; EFT — epicardial fat thickness; FMD — flow media-
ted dilatation
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sure than standard measurements of mitral valve 
inflow [28]. In the present study, the E/E’ ratio in 
the psoriatic patients was significantly higher than 
in controls. Similarly, Bülbül Sen et al. [5] found 
a higher E/E’ ratio in their psoriasis group. In addi-
tion, the present study found that serum chemerin 
levels correlated positively with the E/E’ ratio and 
negatively with the E’ and E’/A’ ratios. Although 
the present study excluded conventional CVD risk 
factors to better evaluate the relationship between 
chemerin levels and diastolic function, it did use 
linear regression analysis, with age, SBP, DBP, 
waist circumference, glucose, and LDL-C as the 
independent variables. The results showed that 
in the psoriatic patients, chemerin levels and age 
were related to diastolic dysfunction independently 
from other risk factors. The association between 
chemerin and diastolic dysfunction may be explained 
by the chronic inflammatory environment of psoria-
sis. Weigert et al. [29] suggested that elevated se-
rum chemerin was strongly related to CRP. Previous 
reports have shown that CRP decreases the produc-
tion of nitric oxide and upregulates the expression 
of angiotensin type-1 receptor, which is associated 
with endothelial dysfunction [30, 31]. Osto et al. [32] 
showed that patients with severe psoriasis showed 
early impairment of coronary microvascular func-
tion, which has also been reported to correlate with 
higher hs-CRP [33]. All of these factors could lead 
to diastolic dysfunction in psoriasis.
Endothelial dysfunction has been recognized 
as an early marker of subclinical atherosclero-
sis. FMD measurements are commonly used to 
evaluate endothelial function, and Balci et al. [34] 
showed that psoriatic patients had lower FMD 
values than normal controls. Gonzalez-Juanatey et 
al. [35] also demonstrated that the FMD percent-
age was lower in psoriatic patients. Similarly, the 
present study found that psoriatic patients had 
impaired FMD compared to controls. This study 
also showed that serum chemerin was strongly 
associated with impaired FMD. 
Epicardial fat tissue is considered a metaboli-
cally active endocrine organ that secretes a number 
of pro-inflammatory and pro-atherogenic cytokines 
[12]. Prior studies have demonstrated associa-
tions between EFT and CVD, insulin resistance, 
coronary calcium score, and metabolic syndrome 
[13, 36]. Previous studies have also reported that 
psoriatic patients had higher EFT values [16, 37]. 
The present study found higher EFT values in 
psoriatic patients than in healthy controls, which 
agrees with the results of previous studies. In addi-
tion, the present study found that serum chemerin 
correlated positively with EFT.
Conclusions
Cardiovascular morbidity and mortality are 
very common in psoriatic patients. However, early 
diagnosis and treatment of patients at high risk for 
CVD reduces mortality rates. The present study 
found that chemerin has a significant relationship 
with EFT and FMD, which are early signs of sub-
clinical atherosclerosis. Also, the serum chemerin 
level is a marker of diastolic dysfunction in psoriatic 
patients. A major limitation of this study was the 
small number of patients enrolled. The results 
should be further analyzed with cause-and-effect 
studies that investigate chemerin’s interactions 
with atherosclerosis. In addition, large population 
studies are needed to prove the study’s hypothesis.
Funding: Istanbul Medeniyet University Research 
Fund supported this study (project number TSG-
-2013-333, TSA-2014-482).
Conflict of interest: None declared
Table 4. Multivariate linear regression analysis with dependent variable E/E’.
Variable Standardized b–coefficient 95% CI p 
Age 0.459 0.021 to 0.110 0.004
Systolic BP 0.287 –0.001 to 0.078 0.058
Diastolic BP –0.137 –0.101 to 0.041 0.404
Chemerin 0.351 0.001 to 0.017 0.026
Glocose 0.012 –0.031 to 0.034 0.932
Waist circumference –0.121 –0.066 to 0.031 0.478
LDL cholesterol 0.079 –0.010 to 0.017 0.589
CI — confidence interval; BP — blood pressure; LDL — low-density lipoprotein
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